Table Graph
      published meta-analysis   sensitivity analysis   studies

Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsBernal, 0 0.45 [0.34; 0.59] ChAdOx1 phase 3 (AstraZeneca), 2020 0.20 [0.02; 1.72] 0.44[0.34; 0.58]Bernal, 0, ChAdOx1 phase 3 (AstraZeneca), 202020%11,636NAnot evaluable hospitalizationdetailed resultsClemens, 2021 0.05 [0.01; 0.41] 0.05[0.01; 0.41]Clemens, 202110%9,433NAnot evaluable symptomatic Covid-19detailed resultsAstraZeneca phase 3 US (D8110C00001), 2021 0.24 [0.18; 0.32] Canada (Nasreen), 2021 0.21 [0.03; 1.52] ChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.26; 0.43] Clemens, 2021 0.33 [0.25; 0.43] Oxford (Pouwels), 2021 0.29 [0.25; 0.33] Public Health England, May 16, 2021 (Bernal), 2021 0.33 [0.28; 0.39] Scotland delta (Sheikh), 2021 0.39 [0.31; 0.50] 0.31[0.28; 0.35]AstraZeneca phase 3 US (D8110C00001), 2021, Canada (Nasreen), 2021, ChAdOx1 phase 3 (AstraZeneca), 2020, Clemens, 2021, Oxford (Pouwels), 2021, Public Health England, May 16, 2021 (Bernal), 2021, Scotland delta (Sheikh), 2021730%174,215moderatenot evaluable asymptomatic COVID casedetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.23; 0.48] 0.33[0.23; 0.48]ChAdOx1 phase 3 (AstraZeneca), 202010%11,636NAnot evaluable infection (PCR positive symptomatic or not)detailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.44 [0.33; 0.59] Oxford (Pouwels), 2021 0.33 [0.29; 0.38] Scotland delta (Sheikh), 2021 0.40 [0.34; 0.47] 0.38[0.32; 0.45]ChAdOx1 phase 3 (AstraZeneca), 2020, Oxford (Pouwels), 2021, Scotland delta (Sheikh), 2021361%161,618moderatenot evaluable severe COVID-19 occurrencedetailed resultsCanada (Nasreen), 2021 0.33 [0.04; 2.63] ChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.02; 14.54] 0.37[0.06; 2.16]Canada (Nasreen), 2021, ChAdOx1 phase 3 (AstraZeneca), 202020%23,745moderatenot evaluable transmission (symptomatic confirmed COVID19)detailed resultsHarris, 2021 0.52 [0.43; 0.62] Public Health England (Harris), 2021 0.53 [0.44; 0.64] 0.52[0.46; 0.60]Harris, 2021, Public Health England (Harris), 202120%seriousnot evaluable vaccine efficacy after dose 1 (and before dose 2)detailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.24 [0.14; 0.41] Scotland cohort, 0 0.06 [0.01; 0.31] 0.15[0.04; 0.54]ChAdOx1 phase 3 (AstraZeneca), 2020, Scotland cohort, 0259%719,355lownot evaluable serious adverse eventsdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.86 [0.64; 1.17] 0.86[0.64; 1.17]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable adverse eventsdetailed resultsAsano, 2022 1.44 [0.71; 2.93] AstraZeneca phase 3 US (D8110C00001), 2021 1.62 [1.54; 1.71] 1.62[1.54; 1.70]Asano, 2022, AstraZeneca phase 3 US (D8110C00001), 202120%32,635NAnot evaluable ATE (Myocardial infarction or ischemic stroke)detailed resultsAstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.44 [0.15; 1.27] AstraZeneca phase 3 US (D8110C00001), 2021 0.12 [0.01; 2.77] Burn (Vaxzevria), 2021 0.81 [0.73; 0.89] Edward (Vaxzevria), 2021 0.98 [0.79; 1.21] Hippisley-Cox, 2021 1.02 [0.98; 1.06] Pottegard, 2021 0.97 [0.78; 1.21] Simpson (ChAdOx1), 2021 0.97 [0.93; 1.02] 0.94[0.87; 1.02]AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 2021, Burn (Vaxzevria), 2021, Edward (Vaxzevria), 2021, Hippisley-Cox, 2021, Pottegard, 2021, Simpson (ChAdOx1), 2021773%56,623moderatenot evaluable ATE with thrombocytopeniadetailed resultsBurn (Vaxzevria), 2021 1.57 [0.65; 3.79] 1.57[0.65; 3.79]Burn (Vaxzevria), 202110%NAnot evaluable deep vein thrombosisdetailed resultsBurn (Vaxzevria), 2021 0.95 [0.83; 1.08] Edward (Vaxzevria), 2021 1.20 [0.81; 1.77] Pottegard, 2021 1.47 [0.94; 2.29] 1.11[0.85; 1.44]Burn (Vaxzevria), 2021, Edward (Vaxzevria), 2021, Pottegard, 2021354%criticalnot evaluable Guillain-Barré syndrome detailed resultsAstraZeneca phase 3 US (D8110C00001), 2021 1.00 [0.03; 29.81] Li X, 2022 0.74 [0.41; 1.33] Patone, 2021 2.04 [1.60; 2.60] 1.26[0.51; 3.11]AstraZeneca phase 3 US (D8110C00001), 2021, Li X, 2022, Patone, 2021380%32,379NAnot evaluable immune thrombocytopenia detailed resultsBurn (Vaxzevria), 2021 2.01 [1.27; 3.19] Edward (Vaxzevria), 2021 0.74 [0.40; 1.37] Simpson (ChAdOx1), 2021 1.98 [1.29; 3.03] 1.49[0.84; 2.63]Burn (Vaxzevria), 2021, Edward (Vaxzevria), 2021, Simpson (ChAdOx1), 2021375%seriousnot evaluable intracranial hemorrhage detailed resultsAsano, 2022 0.33 [0.01; 16.88] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.24 [0.01; 5.40] AstraZeneca phase 3 US (D8110C00001), 2021 0.50 [0.01; 25.21] EPIPHARE (Vaxzevria), 2022 1.06 [0.77; 1.46] Patone, 2021 1.02 [0.90; 1.15] Pottegard, 2021 2.33 [1.09; 4.97] 1.07[0.89; 1.29]Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 2021, EPIPHARE (Vaxzevria), 2022, Patone, 2021, Pottegard, 2021613%56,879NAnot evaluable ischemic strokedetailed resultsAsano, 2022 0.33 [0.01; 16.88] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.32 [0.03; 3.12] AstraZeneca phase 3 US (D8110C00001), 2021 0.13 [0.01; 2.77] Burn (Vaxzevria), 2021 0.75 [0.60; 0.94] Edward (Vaxzevria), 2021 0.96 [0.72; 1.27] EPIPHARE (Vaxzevria), 2022 1.15 [0.97; 1.37] Pottegard, 2021 0.92 [0.55; 1.55] 0.92[0.74; 1.15]Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 2021, Burn (Vaxzevria), 2021, Edward (Vaxzevria), 2021, EPIPHARE (Vaxzevria), 2022, Pottegard, 2021748%56,879seriousnot evaluable Myocardial infarction detailed resultsAsano, 2022 0.33 [0.01; 16.88] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.24 [0.03; 2.18] AstraZeneca phase 3 US (D8110C00001), 2021 0.25 [0.01; 7.46] Burn (Vaxzevria), 2021 0.84 [0.76; 0.93] Edward (Vaxzevria), 2021 0.98 [0.70; 1.37] EPIPHARE (Vaxzevria), 2022 1.29 [1.11; 1.50] Hippisley-Cox, 2021 0.99 [0.95; 1.04] Pottegard, 2021 1.09 [0.68; 1.74] 1.00[0.87; 1.16]Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 2021, Burn (Vaxzevria), 2021, Edward (Vaxzevria), 2021, EPIPHARE (Vaxzevria), 2022, Hippisley-Cox, 2021, Pottegard, 2021870%56,879moderatenot evaluable pulmonary embolismdetailed resultsAsano, 2022 0.33 [0.01; 16.88] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.49 [0.02; 14.52] AstraZeneca phase 3 US (D8110C00001), 2021 0.50 [0.01; 25.21] Burn (Vaxzevria), 2021 1.23 [1.09; 1.39] Edward (Vaxzevria), 2021 1.01 [0.60; 1.71] EPIPHARE (Vaxzevria), 2022 1.41 [1.13; 1.75] Pottegard, 2021 1.79 [1.14; 2.81] 1.28[1.16; 1.41]Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 2021, Burn (Vaxzevria), 2021, Edward (Vaxzevria), 2021, EPIPHARE (Vaxzevria), 2022, Pottegard, 202170%56,879seriousnot evaluable serious adverse events (SAE), anydetailed resultsAsano, 2022 0.16 [0.01; 4.96] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.83 [0.64; 1.07] AstraZeneca phase 3 US (D8110C00001), 2021 0.95 [0.68; 1.33] 0.87[0.71; 1.06]Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 202130%56,879NAnot evaluable splanchnic vein thrombosis (SVT)detailed resultsBurn (Vaxzevria), 2021 1.38 [0.72; 2.65] 1.38[0.72; 2.65]Burn (Vaxzevria), 202110%NAnot evaluable stroke (non-specific, hemorrhagic, and ischemic)detailed resultsBurn (Vaxzevria), 2021 1.01 [0.92; 1.10] Edward (Vaxzevria), 2021 0.86 [0.65; 1.14] 0.99[0.88; 1.10]Burn (Vaxzevria), 2021, Edward (Vaxzevria), 2021212%criticalnot evaluable stroke with thrombocytopeniadetailed resultsBurn (Vaxzevria), 2021 2.21 [0.99; 4.92] 2.21[0.99; 4.92]Burn (Vaxzevria), 202110%NAnot evaluable thrombocytopenia detailed resultsBurn (Vaxzevria), 2021 1.25 [1.19; 1.31] Edward (Vaxzevria), 2021 1.03 [0.93; 1.14] Pottegard, 2021 3.02 [1.82; 5.00] 1.32[1.04; 1.68]Burn (Vaxzevria), 2021, Edward (Vaxzevria), 2021, Pottegard, 2021392%criticalnot evaluable venous thromboembolism detailed resultsAstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.24 [0.01; 5.40] Burn (Vaxzevria), 2021 1.07 [0.98; 1.17] Edward (Vaxzevria), 2021 1.15 [0.83; 1.59] Hippisley-Cox, 2021 1.10 [1.02; 1.18] Pottegard, 2021 1.97 [1.51; 2.56] Simpson (ChAdOx1), 2021 0.91 [0.71; 1.17] 1.16[0.99; 1.36]AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, Burn (Vaxzevria), 2021, Edward (Vaxzevria), 2021, Hippisley-Cox, 2021, Pottegard, 2021, Simpson (ChAdOx1), 2021677%24,244moderatenot evaluable VTE with thrombocytopeniadetailed resultsBurn (Vaxzevria), 2021 1.09 [0.52; 2.29] 1.09[0.52; 2.29]Burn (Vaxzevria), 202110%NAnot evaluable cerebral venous sinus thrombosis (CVST)detailed resultsBurn (Vaxzevria), 2021 2.32 [0.97; 5.56] Pottegard, 2021 20.25 [8.94; 45.85] 6.89[0.82; 57.62]Burn (Vaxzevria), 2021, Pottegard, 2021292%criticalnot evaluable Bell's palsydetailed resultsAstraZeneca phase 3 US (D8110C00001), 2021 1.00 [0.03; 29.81] ChAdOx1 phase 3 (AstraZeneca), 2020 0.98 [0.20; 4.83] Li X, 2022 0.81 [0.66; 0.99] Patone, 2021 1.07 [0.94; 1.21] 0.95[0.77; 1.17]AstraZeneca phase 3 US (D8110C00001), 2021, ChAdOx1 phase 3 (AstraZeneca), 2020, Li X, 2022, Patone, 2021445%56,124NAnot evaluable immediate allergic reactiondetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.07; 58.15] 1.95[0.07; 58.15]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable multiple sclerosisdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.07; 58.15] 1.95[0.07; 58.15]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable myelitisdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.18; 21.52] Li X, 2022 1.45 [0.80; 2.62] Patone, 2021 1.07 [0.87; 1.31] 1.11[0.91; 1.35]ChAdOx1 phase 3 (AstraZeneca), 2020, Li X, 2022, Patone, 202130%23,745NAnot evaluable Potential Immune Gastrointestinal disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.03; 3.13] 0.33[0.03; 3.13]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Musculoskeletal disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.98 [0.06; 15.60] 0.98[0.06; 15.60]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Neuroinflammatory disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 1.22 [0.33; 4.54] 1.22[0.33; 4.54]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Skin disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.73 [0.16; 3.27] 0.73[0.16; 3.27]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Vasculitidesdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.02; 14.54] 0.49[0.02; 14.54]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Thromboembolic eventsdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.15; 1.62] 0.49[0.15; 1.62]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-06-01 05:34 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 759 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons